Original Research
Liver-Specific Deletion of Mouse CTCF Leads to Hepatic Steatosis via Augmented PPARγ Signaling

https://doi.org/10.1016/j.jcmgh.2021.07.016Get rights and content
Under a Creative Commons license
open access

Background & Aims

The liver is the major organ for metabolizing lipids, and malfunction of the liver leads to various diseases. Nonalcoholic fatty liver disease is rapidly becoming a major health concern worldwide and is characterized by abnormal retention of excess lipids in the liver. CCCTC-binding factor (CTCF) is a highly conserved zinc finger protein that regulates higher-order chromatin organization and is involved in various gene regulation processes. Here, we sought to determine the physiological role of CTCF in hepatic lipid metabolism.

Methods

We generated liver-specific, CTCF-ablated and/or CD36 whole-body knockout mice. Overexpression or knockdown of peroxisome proliferator-activated receptor (PPAR)γ in the liver was achieved using adenovirus. Mice were examined for development of hepatic steatosis and inflammation. RNA sequencing was performed to identify genes affected by CTCF depletion. Genome-wide occupancy of H3K27 acetylation, PPARγ, and CTCF were analyzed by chromatin immunoprecipitation sequencing. Genome-wide chromatin interactions were analyzed by in situ Hi-C.

Results

Liver-specific, CTCF-deficient mice developed hepatic steatosis and inflammation when fed a standard chow diet. Global analysis of the transcriptome and enhancer landscape revealed that CTCF-depleted liver showed enhanced accumulation of PPARγ in the nucleus, which leads to increased expression of its downstream target genes, including fat storage-related gene CD36, which is involved in the lipid metabolic process. Hepatic steatosis developed in liver-specific, CTCF-deficient mice was ameliorated by repression of PPARγ via pharmacologic blockade or adenovirus-mediated knockdown, but hardly rescued by additional knockout of CD36.

Conclusions

Our data indicate that liver-specific deletion of CTCF leads to hepatosteatosis through augmented PPARγ DNA-binding activity, which up-regulates its downstream target genes associated with the lipid metabolic process.

Keywords

Liver Steatosis
CTCF
PPARγ
CD36

Abbreviations used in this paper

Ad-PPARγ2
adenoviral peroxisome proliferator-activated receptor γ2
BrdU
bromodeoxyuridine
ChIP-seq
chromatin immunoprecipitation sequencing
cKO
conditional knockout mice
CTCF
CCCTC-binding factor
Ctcffl/fl
floxed CCCTC-binding factor alleles
HNF4α
hepatocyte nuclear factor-4α
H3K27ac
H3K27 acetylation
IL
interleukin
mRNA
messenger RNA
NAFLD
nonalcoholic fatty liver disease
P
promoter
PPAR
peroxisome proliferator-activated receptor
qRT–PCR
quantitative reverse-transcription polymerase chain reaction
RNA-seq
RNA sequencing
ROS
reactive oxygen species
TAD
topologically associating domain
TC
total cholesterol
TG
triglyceride
TNF
tumor necrosis factor
WT
wild-type

Cited by (0)

Conflicts of interest The authors disclose no conflicts.

Funding This work was supported by National Research Foundation of Korea (NRF) grants funded by the Korean government (Ministry of Science and ICT (MSIT)) (2016R1A2B4014183, 2017M3C9A5029978, 2018M3A9D3079290, and 2020R1A2C2013258 to H.-P. Kim).

Authors share co-first authorship.